Novo Nordisk
AI Intelligence Briefcase
Synthesize all available public data, government contracts, patent filings, and funding rounds for Novo Nordisk into a comprehensive strategic report.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No recent patents found.
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Novo Nordisk Stock Rally as Owner Unveils $69 Million Obesity Research Push
Novo Nordisk Owner Bets Big on Obesity Breakthroughs With New $69 Million Program
My Top 5 Dividend Picks For June
Keurig Dr Pepper, Novo Nordisk, Sonoco Products, Domino's Pizza, and Realty Income are top June dividend picks. Read more on KDP, NVO, SON, DPZ, O stocks here.
Novo Nordisk: A Fallen Leader Trading At Fair Value, Not A Bargain
Novo Nordisk has lost GLP-1 leadership against Eli Lilly. Click here to read more about NVO stock and why it is a Hold.
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global GLP-1 Receptor Agonist Market size & share revenue was valued at approximately USD 28.7 Billion in 2025 and is expected to reach USD 34.2 Billion in 2026 and is expected to reach around USD 95.3 Billion by 2035, at a CAGR of 12.1% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Novo Nordisk A/S, Eli Lill
Novo Nordisk to File Oral Wegovy in China
CEO Doustdar expects to submit oral Wegovy for Chinese regulatory approval in "a few months"
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?
These two healthcare leaders have a long history of competing against one another.
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
Novo Nordisk: The Danish Empire Strikes Back
Novo Nordisk leverages Wegovy pill growth and long-term patent protection to overcome a weak 2026 guidance. Read the analysis of NVO stock here.
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.
The next phase of the obesity drug race
Five years after Wegovy’s FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills to compete with the in-demand weight loss shots. Eli Lilly’s next-generation treatment retatrutide produced an average 28% body weight loss in clinical trials, the most ever seen from a weight loss drug. With Pfizer, Amgen, and Zealand Pharma developing new treatments, the weight loss market competition continues to grow rapidly to meet demand.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro